133 related articles for article (PubMed ID: 18202161)
1. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis.
Sarkissian G; Fergelot P; Lamy PJ; Patard JJ; Culine S; Jouin P; Rioux-Leclercq N; Darbouret B
Clin Chem; 2008 Mar; 54(3):574-81. PubMed ID: 18202161
[TBL] [Abstract][Full Text] [Related]
2. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.
Niedworok C; vom Dorp F; Tschirdewahn S; Rübben H; Reis H; Szucs M; Szarvas T
Int Urol Nephrol; 2016 Mar; 48(3):355-61. PubMed ID: 26725072
[TBL] [Abstract][Full Text] [Related]
3. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?
Jung K; Ramankulov A; Schrader M; Miller K; Lein M
Clin Chem; 2008 Nov; 54(11):1927-9. PubMed ID: 18957565
[No Abstract] [Full Text] [Related]
5. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
7. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
9. Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma.
Jiang T; Xie P; Liu H
J Oral Maxillofac Surg; 2016 Mar; 74(3):650-7. PubMed ID: 26454036
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid.
Minamida S; Iwamura M; Kodera Y; Kawashima Y; Tabata K; Matsumoto K; Fujita T; Satoh T; Maeda T; Baba S
Anal Bioanal Chem; 2011 Jul; 401(1):245-52. PubMed ID: 21553213
[TBL] [Abstract][Full Text] [Related]
11. Reduced cytosolic carboxypeptidase 6 (CCP6) level leads to accumulation of serum polyglutamylated DNAJC7 protein: A potential biomarker for renal cell carcinoma early detection.
Li C; Wang J; Hao J; Dong B; Li Y; Zhu X; Ding J; Ren S; Zhao H; Wu S; Tian Y; Wang GQ
Oncotarget; 2016 Apr; 7(16):22385-96. PubMed ID: 26993597
[TBL] [Abstract][Full Text] [Related]
12. Panel of candidate biomarkers for renal cell carcinoma.
Kim DS; Choi YP; Kang S; Gao MQ; Kim B; Park HR; Choi YD; Lim JB; Na HJ; Kim HK; Nam YP; Moon MH; Yun HR; Lee DH; Park WM; Cho NH
J Proteome Res; 2010 Jul; 9(7):3710-9. PubMed ID: 20455597
[TBL] [Abstract][Full Text] [Related]
13. Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.
Zhang L; Jiang H; Xu G; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y
Mol Med Rep; 2015 Jun; 11(6):4093-100. PubMed ID: 25673070
[TBL] [Abstract][Full Text] [Related]
14. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
15. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.
Zhang L; Jiang H; Xu G; Chu N; Xu N; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y; Wang L
Biosci Trends; 2016 Jul; 10(3):210-9. PubMed ID: 27319973
[TBL] [Abstract][Full Text] [Related]
16. Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Kim KH; Lee HH; Yoon YE; Na JC; Kim KS; Han WK
Investig Clin Urol; 2019 Nov; 60(6):425-431. PubMed ID: 31692952
[TBL] [Abstract][Full Text] [Related]
17. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
Xu G; Xiang CQ; Lu Y; Kang XN; Wang WJ; Liao P; Ding Q; Zhang YF
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):858-60. PubMed ID: 18756995
[TBL] [Abstract][Full Text] [Related]
18. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Lymphocyte-Monocyte Ratio Ameliorates the Accuracy of Differential Diagnosis in Non-Metastatic Infiltrative Renal Masses.
Han JH; Yoon YE; Kim SY; Cho YI; Rha KH; Choi YD; Han WK
Yonsei Med J; 2017 Mar; 58(2):388-394. PubMed ID: 28120570
[TBL] [Abstract][Full Text] [Related]
20. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma.
Li G; Cuilleron M; Gentil-Perret A; Cottier M; Passebosc-Faure K; Lambert C; Genin C; Tostain J
Clin Cancer Res; 2003 Dec; 9(17):6441-6. PubMed ID: 14695146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
